Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
The purpose of the phase I/II study is to establish the safety of Combination of Irinotecan and paclitaxel with 5-FU, leucovorin, oxaliplatin and Tislelizumab.
Gastric Cancer Stage IV
DRUG: Oxaliplatin|DRUG: Levo-Leucovorin|DRUG: 5-fluorouracil|DRUG: Paclitaxel|DRUG: Irinotecan|DRUG: Tislelizumab
The maximum dose tolerated, To determine the maximum tolerated dose of POFI with different doses of irinotecan and paclitaxel combined with Tislelizumab in the first month., 1 month
Overall Response Rate, Clinical response of treatment according to RESIST v1.1 criteria (ORR, objective response rate)., 2 years|Progression-free survival, The length of time from enrollment until the time of progression of disease (PFS, progression-free survival)., 2 years|Overall survival, The length of time from enrollment until the time of death (OS, overall survival)., 2 years
The purpose of the phase I/II study is to establish the safety of Combination of Irinotecan and paclitaxel with 5-FU, leucovorin, oxaliplatin and Tislelizumab.